Thryv Therapeutics Announces the Appointment of Esteemed Executive Leader Amy Sehnert, MD, as Chief Medical Officer

Montreal, Quebec – November 20, 2024 – Thryv Therapeutics Inc., a clinical-stage biotechnology company pioneering novel therapies for cardiovascular diseases, is pleased to announce the appointment of Amy Sehnert, MD, as Chief Medical Officer (CMO).  Dr. Sehnert will lead the clinical development and strategy for Thryv Therapeutics’ expanding cardiometabolic product portfolio targeting serum glucocorticoid inducible kinase 1 (SGK1) – a kinase implicated in adverse electrical and structural remodeling of the heart.

Dr. Sehnert is a pediatric cardiologist with 20 years of experience as a serial and founding medical lead at innovative biotech companies introducing precision diagnostics and therapeutics to the clinic.  Dr. Sehnert joins Thryv Therapeutics from Bristol Myers Squibb (BMS), where she held leadership roles of increasing responsibility and most recently served as Vice President and Global Program Lead for cardiovascular assets transitioning from early to late development.  Prior to her time at BMS, Dr. Sehnert served as Vice President, Clinical Science at MyoKardia, Inc., where she played a pivotal role in the development and approval of Camzyos® - a groundbreaking treatment for hypertrophic cardiomyopathy (HCM) - contributing to the $14 billion acquisition of MyoKardia by BMS in 2020.   

“I am thrilled to join Thryv Therapeutics at such an important time in the company’s journey,” said Dr. Sehnert. “Thryv Therapeutics’ cutting-edge approach to cardiovascular diseases aligns with my passion for advancing precision medicine, and I look forward to working with the team to deliver transformative therapies to patients worldwide.” 

Dr. Sehnert has also made notable contributions in other fields of medicine, such as maternal-fetal health, oncology, and genomics, leading early efforts in non-invasive prenatal testing (NIPT) and cell-free DNA applications now in wide clinical use. She holds a Doctor of Medicine degree from the University of Minnesota, completed Pediatrics Residency at University of Colorado, and Fellowship in Pediatric Cardiology at UCSF followed by faculty appointments at UCSF and Stanford University. In 2022 she was recognized as one of the Most Influential Women in Business by the San Francisco Business Times and among the Top 25 Healthcare Technology Leaders of San Francisco. She has co-authored over 60 peer-reviewed publications and has been involved in numerous international collaborations, making her an internationally recognized expert in her field.

“On behalf of Thryv Therapeutics, I am excited to welcome Amy to the team,” said Paul F. Truex, CEO of Thryv Therapeutics. “Dr. Sehnert brings a wealth of medical and clinical development knowledge in the field of cardiometabolic and genetic diseases.   Her extensive experience in designing and executing late-stage clinical trials for genetic and broader cardiovascular diseases and leadership qualities will be invaluable as we enter the next phase of clinical development of our SGK1 portfolio.” 

Dr. Philip Sager, Thryv Therapeutics’ founding Chief Medical Officer, will continue to provide strategic clinical and regulatory guidance as the company’s portfolio advances into later stage clinical studies.  

“Philip and his collaborators originally developed unique insights into the clinical potential for SGK1 in various cardiometabolic diseases and in particular, Long QT Syndrome.  His tireless leadership and relentless passion for exploring these initial ideas advanced Thryv Therapeutics’ portfolio to its current stage,” said Paul F. Truex.  “We’re thankful for his continued, on-going contributions in his new role to all of our clinical programs and we are inspired by his commitment to finding treatments for these patient communities.” 

About Thryv Therapeutics Inc.

Thryv Therapeutics Inc. is a privately owned company based in Montreal, Quebec, Canada. Thryv Therapeutics is pioneering a precision medicine approach to develop potent and highly selective serum glucocorticoid inducible kinase 1 (SGK1) inhibitors to treat heart failure, atrial fibrillation, Long QT Syndrome and other cardiometabolic and cardiorenal diseases.  Numerous animal models have demonstrated that activation of SGK1 leads to inappropriate electrical and structural remodeling of the heart contributing to adverse outcomes in heart failure, atrial fibrillation, and genetic channelopathies, such as Long QT Syndrome.  For more information, please visit www.thryvtrx.com. 

Media Inquiries

brittany@thryvtrx.com | 514 973 0915

Thryv Therapeutics Announces Completion of Phase 1 Dosing of its Second Novel SGK1 Inhibitor THRV-1268 - Future Studies in Heart Failure and Atrial Fibrillation to Commence in 2025

Montreal, Quebec – November 14, 2024 – Thryv Therapeutics Inc., a biotechnology company pioneering treatments for genetic and cardiometabolic conditions, including congenital Long QT Syndrome, heart failure, and atrial fibrillation, has completed phase 1 dosing of its second SGK1 inhibitor.  This study was a first-in-human, randomized, double-blind, placebo-controlled, single and multiple ascending dose study to assess the safety, tolerability, pharmacokinetics, and food effect of THRV-1268 in healthy adult subjects.  The completion of dosing marks a significant milestone in the development of THRV-1268, laying the groundwork for future clinical investigations in heart failure and atrial fibrillation. 

“Completion of this first-in-human study is the initial clinical step with THRV-1268, providing a path towards addressing cardiometabolic diseases where both structural and electrical remodeling lead to adverse CV outcomes in patients with atrial fibrillation and heart failure,” stated Philip Sager, MD, Chief Medical Officer of Thryv Therapeutics. “Building on our initial clinical work with LQT-1213 for Long QT Syndrome, we now have an opportunity to address both the pro-arrhythmic and metabolic pathways of heart failure and atrial fibrillation in patients with underlying metabolic disease.  We look forward to beginning our proof-of-concept studies next year.” 

THRV-1268 is a novel and potent inhibitor of the Serum Glucocorticoid Kinase 1 (SGK1). SGK1 is a PI3-kinase-dependent kinase with its expression and activation regulated by several metabolic signaling pathways that are crucial in cardiometabolic diseases. Thryv Therapeutic’s first SGK1 inhibitor, LQT-1213, repeatedly demonstrated reductions in QTc interval in pre-clinical studies and in patients with the genetic and acquired Long QT Syndrome. SGK1 has been implicated in various pathological conditions, including QTc prolongation, arrhythmias, fibrosis, and heart failure. SGK1 dysfunction is also linked to cardiometabolic stressors such as obesity and hypertension, which are common comorbidities in heart failure.    

Genetic and pharmacological inhibition of SGK1 has been demonstrated to have a protective effect in a mouse model of obesity-related atrial fibrillation. In several preclinical models of heart failure, THRV-1268 mitigated the development of heart failure and fibrosis, and reduced heart failure biomarkers associated with adverse changes in hemodynamic and functional cardiovascular outputs.  These findings demonstrate the potential of SGK1 inhibition in addressing the pathogenesis of heart failure and related cardiometabolic conditions, including atrial fibrillation.  Results from the THRV-1268 non-clinical efficacy program are to be presented at the American Heart Association meeting on November 16 – 18, 2024 in Chicago, Illinois. 

Heart Failure 

Heart failure is a complex clinical syndrome characterized by the heart’s inability to pump sufficient blood to meet the body’s needs. It can manifest in two primary forms: Heart Failure with Reduced Ejection Fraction (HFrEF), where the heart muscle is weakened and cannot contract effectively, leading to a reduced ejection fraction; and Heart Failure with Preserved Ejection Fraction (HFpEF), where the heart muscle contracts normally but is stiff and unable to relax properly, resulting in impaired filling and increased pressure in the heart.  Often coexisting with atrial fibrillation, heart failure can result from various underlying conditions such as coronary artery disease, hypertension and previous heart attacks.  If left untreated, heart failure leads to symptoms like fatigue and shortness of breath that profoundly impact a patient’s quality of life, and significantly increases the risk of severe complications and mortality. 

Atrial Fibrillation 

Atrial fibrillation (AF or AFib) is a prevalent cardiac arrhythmia characterized by irregular and often rapid heartbeats.  Affecting nearly 40 million individuals worldwide, AF significantly diminishes quality of life and heightens the risk of stroke, heart failure and other cardiovascular complications.  Obesity and metabolic disorders are key risk factors for AF, contributing to its rising prevalence.  Effective treatment strategies aim to control heart rate, restore normal heart rhythm and mitigate complications.

About Thryv Therapeutics Inc.

Thryv Therapeutics Inc. is a privately owned company based in Montreal, Quebec, Canada. Thryv Therapeutics is pioneering a precision medicine approach to develop potent and highly selective inhibitors of serum glucocorticoid inducible kinase 1 (SGK1) to treat Long QT Syndrome, heart failure, and atrial fibrillation.  For more information, please visit www.thryvtrx.com. 

Media Inquiries

brittany@thryvtrx.com | 514 973 0915

Thryv Therapeutics Announces Participation in Four Major Upcoming Investor Conferences

Montreal, Quebec – November 6, 2024 – Thryv Therapeutics Inc., a clinical-stage biotechnology company pioneering novel therapies for cardiovascular diseases, is pleased to announce its participation in four prominent healthcare investor conferences over the coming weeks, providing critical updates on its advancements in precision medicine.

Stifel Healthcare Conference 2024 

• Format: Presentation and one-on-one investor meetings 

• Date: Monday, November 18, 2024, from 1:50 p.m. to 2:20 p.m. ET 

• Location: Lotte New York Palace Hotel, New York, NY 

At the Stifel Healthcare Conference, Thryv Therapeutics will present key updates on its precision medicine approach, targeting novel treatments for Long QT Syndrome, heart failure and atrial fibrillation. Thryv's management team will also be available for one-on-one meetings throughout the day on Monday, November 18. To arrange a meeting, please contact admin@thryvtrx.com. 

Jefferies London Healthcare Conference 2024 

• Dates: November 19-21, 2024 

• Location: London, UK 

To arrange a meeting at Jefferies, please contact admin@thryvtrx.com. 

Piper Sandler 36th Annual Healthcare Conference 

• Format: One-on-one investor meetings 

• Dates: December 3-5, 2024 

• Location: New York, NY 

To arrange a meeting at Piper Sandler, please contact admin@thryvtrx.com. 

Wells Fargo Virtual Private Biotech Symposium 

• Format: One-on-one investor meetings 

• Date: December 12, 2024 

To arrange a virtual meeting, please contact admin@thryvtrx.com. 

About Thryv Therapeutics Inc.

Thryv Therapeutics Inc. is a privately owned company based in Montreal, Quebec, Canada. Thryv Therapeutics is pioneering a precision medicine approach to develop potent and highly selective inhibitors of serum glucocorticoid inducible kinase 1 (SGK1) to treat Long QT Syndrome, heart failure, and atrial fibrillation.  For more information, please visit www.thryvtrx.com. 

Media Inquiries

brittany@thryvtrx.com | 514 973 0915

Thryv Therapeutics to Sponsor and Participate in the 2024 International SADS Foundation Family Conference in Chicago

Montreal, Quebec – November 4, 2024 – Thryv Therapeutics Inc., a clinical-stage biotechnology company, is proud to announce its sponsorship and active participation in the 2024 International Sudden Arrhythmia Death Syndromes (SADS) Foundation Family Conference, taking place in Chicago, Illinois from November 8th to 9th, 2024.

This highly anticipated event, organized in partnership with Northwestern University and Ann & Robert H. Lurie Children’s Hospital, unites leading global experts in inherited arrhythmias, along with patients and families affected by conditions such as Long QT Syndrome (LQTS). The conference serves as a vital forum for sharing cutting-edge research, advancements in treatment, and personal stories from the SADS community. 

“We are honored to sponsor and participate in this important gathering,” said Paul Truex, Chairman and CEO of Thryv Therapeutics. “Our mission is to offer meaningful solutions for patients with Long QT Syndrome, and we look forward to connecting with the SADS community, sharing our progress, and learning from the invaluable experiences of patients and families.” 

As part of its sponsorship, Thryv Therapeutics will deliver a 10-minute presentation, followed by a Q&A session, during both the healthcare professional and family sessions.  In addition, Paul Truex will participate in a live interview during the reception, engaging directly with attendees.  David Hutton, a renowned advocate for Long QT Syndrome (LQTS) patients, will also be attending on behalf of Thryv.  David Hutton works closely with patients and their families, sharing their stories to raise awareness and strengthen community support for those living with inherited cardiac conditions. 

The International SADS Foundation Family Conference offers an unparalleled opportunity for patients, caregivers, and healthcare providers to exchange insights, discuss the latest advances in treatment, and collaborate on strategies for improving patient outcomes.  It fosters a supportive environment where families and medical professionals can connect and ensure that those affected by these conditions receive the care and information they need from the SADS Foundation and its experts. 

For more details about the conference, visit the SADS Foundation website. 

About SADS Foundation 

The Sudden Arrhythmia Death Syndromes (SADS) Foundation is committed to saving lives and providing support to families affected by genetic predispositions to sudden cardiac death caused by heart rhythm abnormalities.  The Foundation supports individuals living with inherited channelopathies and cardiomyopathies, including conditions such as Long QT Syndrome, Catecholaminergic Polymorphic Ventricular Tachycardia (CPVT), Brugada Syndrome, Short QT Syndrome, and Arrhythmogenic Cardiomyopathy (ACM). 

For more information, visit the SADS Foundation website. 

About Thryv Therapeutics Inc.

Thryv Therapeutics Inc. is a privately owned company based in Montreal, Quebec, Canada. Thryv Therapeutics is pioneering a precision medicine approach to develop potent and highly selective inhibitors of serum glucocorticoid inducible kinase 1 (SGK1) to treat Long QT Syndrome, atrial fibrillation and heart failure.  For more information, please visit www.thryvtrx.com. 

Media Inquiries

brittany@thryvtrx.com | 514 973 0915

Thryv Therapeutics Announces Four Abstracts Accepted for AHA 2024 Annual Scientific Sessions

Montreal, Quebec – October 23, 2024 – Thryv Therapeutics Inc., a biotechnology company pioneering precision treatments for cardiovascular conditions, including congenital Long QT Syndrome, atrial fibrillation and heart failure, is proud to announce the acceptance of four abstracts for presentation at the prestigious American Heart Association’s (AHA) 2024 Annual Scientific Sessions.  The event, which brings together global experts to exchange the latest advancements in cardiovascular science, clinical care, and research, will take place from November 16 - 18, 2024, at the McCormick Place Convention Center in Chicago, Illinois. 

Thryv Therapeutics is honored to contribute to this important dialogue with its recent research. 

Presentation Details 

• Poster Presentation Title 1: Serum Glucocorticoid Regulated Kinase 1 (SGK-1) Inhibitor Reduced Hypertension in a Salt-Sensitive Hypertension Model of Heart Failure with Preserved Ejection Fraction 

Presentation Date: Saturday, November 16, 2024  

Presentation Time: 2:00-3:00 p.m. CST 

Location: Zone 2 

• Poster Presentation Title 2: Serum and Glucocorticoid Regulated Kinase 1 (SGK1) Inhibition Induces Anti-Fibrotic and Anti-Inflammatory Responses: Relevance to Cardiac Fibrosis   

Presentation Date: Monday, November 18, 2024 

Presentation Time: 1:30-2:30 p.m. CST 

Location: Zone 1, Science & Technology Hall 

• Poster Presentation Title 3: SGK1 inhibition attenuated left ventricular thickening and diastolic dysfunction in a mouse model of Heart Failure with Preserved Ejection Fraction 

Presentation Date: Saturday, November 16, 2024 

Presentation Time: 2:00-3:00 pm CST 

Location: Zone 2 

• Poster Presentation Title 4: SGK1 inhibition shortens action potential duration in LQT3 mice and LQT2 rabbits via inhibition of late sodium current 

Presentation Date: Sunday, November 17, 2024 

Presentation Time: 3:15-3:20 p.m. CST 

Location: Zone 4, Moderated Digital Poster 23 

To schedule a meeting with a representative from Thryv at the AHA Annual Scientific Sessions, please email: admin@thryvtrx.com.  

For more information about the AHA Annual Scientific Sessions, please visit: ahascientificsessions.org 

About Thryv Therapeutics Inc.

Thryv Therapeutics Inc. is a privately owned company based in Montreal, Quebec, Canada. Thryv Therapeutics is pioneering a precision medicine approach to develop highly selective SGK1 inhibitors to treat Long QT Syndrome, atrial fibrillation and heart failure, with potent and selective inhibitors of serum glucocorticoid inducible kinase.  For more information, please visit www.thryvtrx.com.

Media Inquiries

brittany@thryvtrx.com | 514 973 0915

Thryv Therapeutics Receives Positive Top-Line Results from Wave I Part 2 Clinical Study in Long QT Syndrome Type 2 and Type 3 Patients

Montreal, Quebec – October 15, 2024 – Thryv Therapeutics Inc., a clinical-stage biotechnology company, received positive top-line results from the Wave I Part 2 proof-of-concept clinical study evaluating LQT-1213 for the treatment of congenital Long QT Syndrome (cLQTS) Types 2 and 3. LQT-1213, a potent and selective serum glucocorticoid inducible kinase 1 (SGK1) inhibitor, demonstrated clinically meaningful and statistically significant reductions in the QTcF interval (a measure of how long it takes the heart to “reset” between beats) after only two days of dosing in patients with cLQTS Types 2 and 3.  LQT-1213 appeared to be generally well-tolerated in the study with no drug-related adverse events (AEs) reported.

Congenital LQTS is a rare genetic condition that affects the heart’s electrical system, leading to an increased risk of life-threatening arrhythmias in children and adults. While Wave I Part 1 evaluated the effect of LQT-1213 in a model of LQTS induced by the drug dofetilide, Wave 1 Part 2 included, for the first time, patients with genetically confirmed congenital LQTS Types 2 and 3, providing direct clinical insights into the acute efficacy of LQT-1213 in the targeted patient population.  It is believed that reductions in QTcF will reduce arrhythmic risk in pediatric and adult patients with prolonged QTc intervals.

"We are excited about the positive top-line results from the Wave I Part 2 study in cLQTS Types 2 and 3 patients. Two days of treatment with LQT-1213 demonstrated rapid and clinically meaningful reductions in QTcF.  As well, a clear dose level effect was seen with the highest dose of LQT-1213 reducing QTcF for all key endpoints of the study,” said Philip Sager, MD, FAHA, Chief Medical Officer of Thryv Therapeutics. "The totality of LQT-1213 treatment effects, which are on top of beta blocker therapy, has allowed us to engage regulatory agencies about our next steps towards a pivotal program in patients with congenital Long QT Syndrome.”

Study Highlights

Wave I is a multi-part, proof-of-concept clinical study designed to evaluate the safety and efficacy of LQT-1213 in reducing QT in patients with both acquired and congenital forms of Long QT Syndrome.  Further details about the study can be found at www.clinicaltrials.gov (NCT05906732).

Full data from the Wave I Part 2 study in congenital LQTS Types 2 and 3 will be presented at an upcoming scientific conference in 2025.  Part 3 of the Wave I study will enroll patients with cLQTS Type 1 who demonstrate continued prolongation of their QT interval despite standard of care.

About LQT-1213

LQT-1213 is a potent and selective serum glucocorticoid regulated kinase 1 (SGK1) inhibitor being developed as an investigational therapeutic to treat Long QT Syndrome Types 1, 2, and 3.  By targeting SGK1, LQT-1213 aims to reduce the prolonged QTc interval in children and adults with LQTS, thereby decreasing the risk of life-threatening arrhythmias.  Currently, LQT-1213 is being evaluated in clinical studies for its efficacy and safety in treating both congenital and acquired LQTS.   LQT-1213 has been granted Orphan Drug Designation by the US FDA for the treatment of congenital Long QT Syndrome.

About Long QT Syndrome

LQTS is a disorder of the electrical system that results in the heartbeat taking longer than usual to “reset” between beats, measured on the ECG as the QTc interval. LQTS can be either congenital or acquired due to certain drugs.  Congenital LQTS is a set of rare orphan diseases in which people are genetically predisposed to chronic prolongation of their QTc interval (commonly more than 480 milliseconds), leading to increased risk of torsades de pointes, a lethal cardiac arrhythmia that can cause sudden cardiac death. Acquired Long QT may develop from the administration of therapies which block electrical pathways in the heart, leading to a similar mechanistic prolongation of QTc and risk of sudden cardiac death.

About Thryv Therapeutics Inc.

Thryv Therapeutics Inc. is a privately owned company based in Montreal, Quebec, Canada. Thryv Therapeutics is pioneering a precision medicine approach to develop highly selective SGK1 inhibitors to treat Long QT Syndrome, atrial fibrillation and heart failure, with potent and selective inhibitors of serum glucocorticoid inducible kinase.  For more information, please visit www.thryvtrx.com.

Media Inquiries

brittany@thryvtrx.com | 514 973 0915

Thryv Therapeutics Granted FDA Orphan Drug Designation for LQT-1213 in Long QT Syndrome Treatment

Montreal, Quebec – October 1, 2024 – Thryv Therapeutics Inc., a clinical stage biotech company dedicated to developing treatments for rare and life-threatening cardiovascular indications, today announced that the United States Food and Drug Administration (FDA) has granted Orphan Drug Designation to LQT-1213 for the treatment of Long QT Syndrome (LQTS).  LQT-1213 is a novel, first-in-class SGK1 inhibitor specifically designed to treat congenital LQTS.  Thryv has developed a series of SGK1 inhibitors for the treatment of cardiometabolic stress associated with various arrhythmic diseases including LQTS, atrial fibrillation, and heart failure.

“We are pleased with the FDA’s Orphan Drug Designation for LQT-1213 based partly on emerging positive clinical data from our Wave 1 clinical study in patients with Long QT Syndrome” said Debra Odink, PhD, President and Chief Development Officer of Thryv Therapeutics. “People with Long QT Syndrome deserve a properly studied and FDA-approved therapy to help in their battle against this potentially lethal genetic disease. There is currently no FDA-approved therapy for people with Long QT Syndrome. This designation reinforces the potential of LQT-1213 to fulfill this unmet need and provides critical incentives for Thryv to accelerate our efforts to deploy prospectively designed, pivotal efficacy studies in people with congenital Long QT Syndrome.  We remain focused on bringing innovative treatments to adults and children with rare diseases who have limited options.” 

Following a request from the FDA, clinical data from the ongoing Wave I clinical study in people with congenital LQTS was provided to the Office of Orphan Products Designation.  Shortly thereafter, the company received notification that its request for Orphan Drug Designation was approved. 

The FDA Orphan Drug Designation is a special status granted to drugs and biologics targeting rare diseases, defined as those affecting fewer than 200,000 people in the United States.  This designation offers numerous benefits to support the development of treatments for rare conditions, including tax credits for clinical trial costs, exemption from certain FDA fees, and up to seven years of market exclusivity following FDA approval. 

About LQT-1213 

LQT-1213 is a potent and selective serum glucocorticoid regulated kinase 1 (SGK1) inhibitor being developed as an investigational therapeutic to treat Long QT Syndrome Type 1, 2, and 3.  By targeting SGK1, LQT-1213 aims to reduce the prolonged QTc interval in people with LQTS, thereby decreasing the risk of life-threatening arrhythmias.  Currently, LQT-1213 is being evaluated in clinical studies for its efficacy and safety in treating congenital LQTS.   

Additional information about the on-going Wave I clinical study is available at www.clinicaltrials.gov using identifier: NCT05906732. 

About Thryv Therapeutics Inc.

Thryv Therapeutics Inc. is a privately owned company based in Montreal, Quebec, Canada. Thryv Therapeutics is pioneering a precision medicine approach to develop highly selective SGK1 inhibitors to treat Long QT Syndrome, atrial fibrillation and heart failure, with potent and selective inhibitors of Serum Glucocorticoid inducible Kinase. For more information, please visit www.thryvtrx.com.

Media Inquiries

brittany@thryvtrx.com | 514 973 0915

Thryv Therapeutics to Participate in Fireside Chat During 2024 RBC Capital Markets Biotechnology Private Company Virtual Conference

• Thryv Therapeutics to participate in a fireside chat on Tuesday, October 1st, 2024, from 10:30 a.m. to 11:00 a.m. ET.  

Montreal, Quebec – September 23, 2024 – Thryv Therapeutics announced today its participation in the upcoming 2024 RBC Capital Markets Private Company Virtual Conference. Thryv will attend on Tuesday, October 1st, 2024, and will sit for a fireside chat from 10:30 a.m. to 11:00 a.m. ET.

Company management will also host and participate in one-on-one investor meetings at the conference. To schedule one-on-one meetings with the team, please contact admin@thryvtrx.com.

About Thryv Therapeutics Inc.

Thryv Therapeutics Inc. is a privately owned company based in Montreal, Quebec, Canada. Thryv Therapeutics is pioneering a precision medicine approach to treat indications including Congenital Long QT Syndromes (LQTS), atrial fibrillation and heart failure, with potent and selective inhibitors of Serum Glucocorticoid inducible Kinase (SGK1). For more information, please visit www.thryvtrx.com.

Media Inquiries

brittany@thryvtrx.com | 514 973 0915

Thryv Therapeutics to Participate at the 2024 Jefferies Global Healthcare Conference

Montreal, Quebec – May 24, 2024 – Thryv Therapeutics is pleased to announce that it will be hosting investor meetings at the Jefferies Global Healthcare Conference on Tuesday, June 4, 2024, at the Hyatt Grand Central New York. This year’s gathering will bring together 3,000 leading executives to address near-and long-term investment opportunities as well as current trends driving healthcare in the U.S. and internationally.

To schedule a meeting with Thryv Therapeutics throughout the day, please contact admin@thryvtrx.com.

About Thryv Therapeutics Inc.

Thryv Therapeutics Inc. is a privately owned company based in Montreal, Quebec, Canada. Thryv Therapeutics is pioneering a precision medicine approach to treat indications including Congenital Long QT Syndromes (LQTS), atrial fibrillation and heart failure, with potent and selective inhibitors of Serum Glucocorticoid inducible Kinase (SGK1). For more information, please visit www.thryvtrx.com.

Media Inquiries

brittany@thryvtrx.com | 514 973 0915

Thryv Therapeutics to Present Preclinical Data of SGK1 Inhibition in Models of Drug-Induced QT Prolongation at the 2024 Heart Rhythm Society Meeting

Montreal, Quebec – May 7, 2024 – Thryv Therapeutics Inc., a biotechnology company pioneering precision treatment to treat indications including Congenital Long QT Syndrome, atrial fibrillation, and heart failure, today announced a poster presentation of SGK1 inhibition in models of Drug-Induced QT prolongation at the 2024 Heart Rhythm Society meeting in Boston, MA. This presentation will take place on Friday, May 17th, from 10:30 a.m. to 12:30 p.m. ET. The meeting will commence with a presentation by Thryv co-founder and Principal Scientific Advisor, Dr. Saumya Das, at the Stanford Biodesign New Arrhythmia Technologies Retreat in Boston, where he will discuss Small Molecules for Arrhythmia Therapy.

Heart Rhythm 2024

Poster Presentation Title: Attenuation of Drug-Induced QT Prolongation in Guinea Pig Isolated Heart and Anesthetized Dog Models by serum/glucocorticoid-regulated kinase 1 (SGK-1) Inhibitors. 

Date and Time: Friday, May 17th from 10:30 a.m. to 12:30 p.m. ET.

2024 Stanford BioDesign Arrhythmia Technologies Retreat

Presentation Title: Small Molecules for Arrhythmia Therapy 

Presenter: Saumya Das, MD, PhD 

Date and Time: Wednesday, May 15th at 9:04 a.m.

About Thryv Therapeutics Inc.

Thryv Therapeutics Inc. is a privately owned company based in Montreal, Quebec, Canada. Thryv Therapeutics is pioneering a precision medicine approach to treat indications including Congenital Long QT Syndromes (LQTS), atrial fibrillation and heart failure, with potent and selective inhibitors of Serum Glucocorticoid inducible Kinase (SGK1). For more information, please visit www.thryvtrx.com.

Media Inquiries

brittany@thryvtrx.com | 514 973 0915

Thryv Therapeutics to Participate at the Piper Sandler Spring Biopharma Symposium

Montreal, Quebec – April 10, 2024 – Thryv Therapeutics is pleased to announce that it will be hosting investor meetings at the Piper Sandler Spring Biopharma Symposium on Tuesday, April 16, 2024, at the Encore Boston Harbor.

To schedule a 1x1 meeting with Thryv Therapeutics, email corporateaccess@psc.com.

About Thryv Therapeutics Inc.

Thryv Therapeutics Inc. is a privately owned company based in Montreal, Quebec, Canada. Thryv Therapeutics is pioneering a precision medicine approach to treat indications including Congenital Long QT Syndromes (LQTS), atrial fibrillation and heart failure, with potent and selective inhibitors of Serum Glucocorticoid inducible Kinase (SGK1). For more information, please visit www.thryvtrx.com.

Media Inquiries

daphne@thryvtrx.com | 514 973 0915

Thryv Therapeutics to Present at the 2024 Bloom Burton & Co. Healthcare Investor Conference

• Thryv to present on Tuesday, April 16th, 2024, from 3:00 p.m. to 3:30 p.m. ET.

Montreal, Quebec – April 9, 2024 – Thryv Therapeutics is pleased to announce its selection as a featured presenter at the 2024 Bloom Burton & Co. Healthcare Investor Conference. The virtual presentation will take place on Tuesday, April 16th, 2024, from 3:00 p.m. to 3:30 p.m. ET.

The Thryv team will also be available for one-on-one meetings throughout the day on Tuesday, April 16th and Wednesday, April 17th. To schedule one-on-one meetings with the team, please contact admin@thryvtrx.com.

About Thryv Therapeutics Inc.

Thryv Therapeutics Inc. is a privately owned company based in Montreal, Quebec, Canada. Thryv Therapeutics is pioneering a precision medicine approach to treat indications including Congenital Long QT Syndromes (LQTS), atrial fibrillation and heart failure, with potent and selective inhibitors of Serum Glucocorticoid inducible Kinase (SGK1). For more information, please visit www.thryvtrx.com. 

Media Inquiries

daphne@thryvtrx.com | 514 973 0915

Thryv Therapeutics to Present Results of Wave I Part 1 Clinical Study at American College of Cardiology Conference in Atlanta, Georgia on April 7th, 2024

• Treatment with LQT-1213 demonstrated statistically significant and clinically meaningful reductions in dofetilide-induced QTc prolongation.

• Larger treatment effects seen in pre-defined subgroups of individuals with largest increases in QTc from baseline and longest QTc intervals.

• No meaningful safety findings, including no effects on ECG morphology.

Montreal, Quebec – March 26th, 2024 – Thryv Therapeutics is pleased to announce the presentation of its poster: SGK1 inhibitor LQT-1213 significantly attenuates dofetilide-induced QT prolongation in humans: Results of the WAVE I Clinical Study at the American College of Cardiology Conference.  Thryv’s poster presentation will be presented on Sunday, April 7th from 12:15 p.m. - 1:00 p.m. in Hall B4-5. Representatives from Thryv will also be present throughout the weekend to meet with cardiologists and electrophysiologists to gain insights into various elements of their development program strategies. To learn more about this initiative, please contact admin@thryvtrx.com.

The WAVE I proof of concept clinical study evaluated LQT-1213 for the reduction of QTcF in individuals with dofetilide-induced long QT Syndrome (“LQTS”).  LQT-1213 is a potent and selective inhibitor of Serum Glucocorticoid inducible Kinase 1 (SGK1), which is implicated in QTc prolongation. In the WAVE I study, following two days of treatment with dofetilide (baseline) – an agent known to prolong QTc – individuals with meaningful increases in their QTc interval received six days of increasing LQT-1213 doses with a consistent dose of dofetilide.  Individuals were continuously monitored and received regular ECGs to assess the safety and efficacy of LQT-1213.  Mean reductions of QTcF from baseline (measured as QTcF) were statistically significant beginning with the first evaluable time point of the primary analysis and were sustained during the peak dofetilide-induced prolongation.

In a predefined subset of individuals who experienced larger dofetilide-induced prolongation of QTcF, individuals treated with LQT-1213 achieved more robust, clinically meaningful reductions of QT consistent with scientific evidence of SGK1 activation in LQTS.  LQT-1213 was well tolerated with no serious adverse events or treatment-related study discontinuations.  No QTcF over-shortening was observed in the study.  There were no observed changes in ECG morphology, heart rate or blood pressure. 

Part 2 of the WAVE I clinical study is currently enrolling a small cohort of individuals with genetically confirmed congenital Long QT Syndrome Type 2 and Type 3.  This study will provide information about the safety of LQT-1213 before initiation of Phase 3 clinical studies in congenital LQTS patients.   Data from this study is expected in the second quarter of 2024. More about the WAVE I (Parts 1 and 2) can be found at https://www.clinicaltrials.gov/study/NCT05906732.

Long QT Syndrome, or LQTS, is a disorder of the heart’s electrical system causing the lower chambers of the heart to contract and release too slowly. LQTS can be either congenital or acquired.  Congenital LQTS is a set of rare orphan diseases in which people are genetically predisposed to chronic prolongation of their QTc interval (commonly more than 480 milliseconds), leading to increased risk of torsades de pointes, a lethal cardiac arrhythmia that causes sudden cardiac death. Acquired Long QT may develop from the administration of therapies which block electrical pathways in the heart, leading to a similar mechanistic prolongation of QT and risk of sudden cardiac death.

About Thryv Therapeutics Inc.

Thryv Therapeutics Inc. is a privately owned company based in Montreal, Quebec, Canada. Thryv Therapeutics is pioneering a precision medicine approach to treat indications including Congenital Long QT Syndromes (LQTS), atrial fibrillation and heart failure, with potent and selective inhibitors of Serum Glucocorticoid inducible Kinase (SGK1). For more information, please visit www.thryvtrx.com.

Media Inquiries

daphne@thryvtrx.com | 514 973 0915

Thryv Therapeutics to Present at Evercore ISI 2024 Emerging Biotech Conference

• Thryv Therapeutics to present virtually at Evercore ISI 2024 Emerging Biotech Conference on Wednesday, February 28th from 2:15-2:45 p.m. ET.

Montreal, Quebec – February 20, 2024 – Thryv Therapeutics is pleased to announce its selection as a featured presenter at the Evercore ISI 2024 Emerging Biotech Conference that is taking place virtually on February 28th and 29th, 2024. Thryv’s virtual presentation will be on February 28th from 2:15-2:45 p.m. ET.

About Thryv Therapeutics Inc.

Thryv Therapeutics Inc. (previously LQT Therapeutics Inc.) is a privately owned company based in Montreal, Quebec, Canada. Thryv Therapeutics is pioneering a precision medicine approach to treat indications including Congenital Long QT Syndromes (LQTS), atrial fibrillation and heart failure with potent and selective inhibitors of Serum Glucocorticoid inducible Kinase (SGK1). For more information, please visit www.thryvtrx.com.

Media Inquiries

daphne@thryvtrx.com | 514 973 0915

2023 Year End Report

As we bid farewell to 2023, it is with great enthusiasm that we share with you the accomplishments and progress that the Thryv team has achieved over the past year.

Thryv has grown to include 17 full-time employees, and we are grateful for the dedication and talent that each team member brings to our mission.

Long QT Syndrome

In the realm of Long QT Syndrome, our progress has been substantial. The completion of our Phase 1 healthy volunteer study demonstrated that LQT-1213 was well tolerated, with good bioavailability and predictable pharmacokinetics. Furthermore, the data from our WAVE I Part 1 clinical proof of efficacy study was particularly encouraging. It showed that LQT-1213 rapidly and significantly reduces the QTc interval in individuals with prolonged QTc induced by dofetilide, mimicking Long QT Syndrome Type 2. Thanks to the extraordinary efforts of our team, the WAVE I Part 2 study is underway, now focusing not only on evaluating safety, tolerability, and pharmacokinetics of LQT-1213, but providing a glimpse of efficacy in patients diagnosed with Long QT Syndrome Type 2 or Type 3. We would like to extend our appreciation to the teams at the Sudden Arrhythmia Death Syndromes Foundation (SADS), Mayo Clinic, and the University of Rochester for their pivotal roles in facilitating our efforts to provide patients with Long QT Syndrome a potential new therapeutic choice.

In addition to these clinical developments, our team has made significant contributions to the scientific community this year. We have published three influential papers related to Long QT Syndrome research. The first, titled "SGK1 Inhibition Attenuates Action Potential Duration in Reengineered Heart Cell Models of Drug-Induced QT Prolongation," and second titled “SGK1 inhibition attenuated the action potential duration in patient- and genotype-specific re-engineered heart cells with congenital long QT syndrome” were featured in the Heart Rhythm Society Journal. The first study demonstrated the efficacy of two novel SGK1 inhibitors in IPSC-CM models displaying dofetilide-induced action potential duration prolongation, and the second study sought to test the efficacy of novel, selective SGK1 inhibitors in induce pluripotent stem cell–derived cardiomyocyte (iPSC-CM) models of LQTS. Our third paper, "Gene- and Variant-Specific Efficacy of Serum/Glucocorticoid-Regulated Kinase 1 Inhibition in Long QT Syndrome Types 1 and 2," was published by the European Society of Cardiology. This study showed that SGK1 inhibition shortens action potential duration in individuals with Long QT Syndrome Types 1 and 2.

Atrial Fibrillation and Heart Failure

Our endeavors in atrial fibrillation and heart failure have been equally promising. We successfully demonstrated the preventive effect of an SGK1 inhibitor in an animal model of high-fat diet-induced atrial fibrillation and our abstract, A Novel SGK1 Inhibitor (SGK1-I), Prevents Obesity-Related Atrial Fibrillation, was selected for an oral presentation at the American Heart Association Annual Scientific Sessions. We would like to thank our collaborator, Dr. Aneesh Bapat, Cardiac Electrophysiologist at Massachusetts General Hospital and Instructor in Medicine, Harvard Medical School, who served as this study’s investigator.

In the realm of Heart Failure, to further understand the cardiometabolic benefit of SGK-1 inhibition, two new preclinical studies for heart failure with preserved ejection fraction (HFpEF) have been initiated, with data expected in early 2024.

Furthermore, the preclinical studies required for human dosing are now completed and we are gearing up for a healthy volunteer Phase 1 study early next year for our third novel SGK1 inhibitor.

Oncology

In the field of oncology, we have made impressive strides. Our research team demonstrated the efficacy of THRV-1257 in delaying and reversing resistance to standard-of-care treatment in a mouse xenograft model of anaplastic thyroid cancer. Perhaps the most significant milestone was the FDA clearance we received for an Investigational New Drug (IND) application for THRV-1257 in anaplastic thyroid cancer (ATC). This achievement paves the way for clinical studies in humans, which we anticipate commencing in 2024.

We attended the American Thyroid Cancer Annual meeting held in October and presented a poster titled "The SGK1 Inhibitor THRV-1257: Robust Tumor Regression and Overcoming Resistance to Standard of Care Dabrafenib Plus Trametinib in a Mouse Model of Anaplastic Thyroid Cancer (ATC) with BRAFV600E Mutation”. This presentation demonstrated the ability of THRV-1257 to induce significant tumor regression and successfully combat resistance when combined with the standard of care treatment, dabrafenib + trametinib. These results provide support for the clinical evaluation of THRV-1257 in patients with Anaplastic Thyroid Cancer and the BRAFV600E mutation.  THRV-1257 also promoted a significant increase in tumor growth inhibition when combined with the standard of care treatment in a mouse xenograft model of colorectal cancer, which could enable future study in this indication as well.

The Thryv team would like to express its gratitude to the International Thyroid Oncology Group (ITOG) for their continuous support in providing guidance and recommendations for our clinical development. We would like also to thank our collaborator, Dr. Antonio Di Cristofano, at the NCI-designated Montefiore Einstein Comprehensive Cancer Center, for a great year of results that should culminate in the publication of two research papers highlighting the potential of SGK1 inhibition in ATC.

Advisory Boards

In 2023, Thryv convened three advisory board meetings featuring Key Opinion Leaders (KOLs) in their respective fields. The inaugural meeting was the Commercial Advisory Board Meeting, where participants engaged in discussions regarding our strategic commercial roadmap, encompassing all three of our programs. Additionally, we reconvened our Long QT Syndrome Advisory Board and organized dedicated advisory board meetings for oncology and atrial fibrillation, where attending physicians and KOLs provided guidance on our clinical pathways for all three programs.

Thanks for a Great Year

These achievements are the result of relentless dedication, rigorous research, and unwavering commitment to improving the lives of those affected by these conditions. We want to extend our gratitude to the entire Thryv community. A special thank you goes out to our Board of Directors and our Investors for their invaluable contributions. 

As we venture into 2024, we do so with optimism and determination. The past 12 months have been a whirlwind of activity, and we are excited about what’s to come in the new year.

Wishing all our supporters, patients, and families a healthy and happy new year!

Sincerely,

Debra Odink

President & Chief Development Officer

Thryv Therapeutics to Present at the 2023 RBC Capital Markets Private Company Conference

• Thryv to present virtually on Thursday, December 14th, 2023, from 10:40 a.m. to 11:10 a.m. ET.

Montreal, Quebec – December 11, 2023 – Thryv Therapeutics is pleased to announce its selection as a featured presenter at the 2023 RBC Capital Markets Private Company Conference. The virtual presentation will take place on Thursday, December 14th, 2023, from 10:40 a.m. to 11:10 a.m. ET.

The Thryv team will also be available for one-on-one meetings on Wednesday, December 13th and Thursday December 14th. To schedule one-on-one meetings with the team, please contact admin@thryvtrx.com.

About Thryv Therapeutics Inc.

Thryv Therapeutics Inc. (previously LQT Therapeutics Inc.) is a privately owned company based in Montreal, Quebec, Canada. Thryv Therapeutics is pioneering a precision medicine approach to treat Congenital Long QT Syndromes (LQTS), atrial fibrillation, heart failure and resistant cancers with potent and selective inhibitors of Serum Glucocorticoid inducible Kinase (SGK1). For more information, please visit www.thryvtrx.com.

Media Inquiries

daphne@thryvtrx.com | 514 973 0915

Thryv Therapeutics’ CEO, Paul Truex, to Present at Piper Sandler’s 35th Annual Healthcare Conference

• Paul Truex to present Wednesday, November 29th at 3:50-4:10PM in Harlem Track, Kennedy 2, 4th floor.

Montreal, Quebec – November 10, 2023 – Thryv Therapeutics is pleased to announce its selection as a featured presenter at the Piper Sandler 35th Annual Healthcare Conference, held from November 28th to November 30th, 2023, at Lotte New York Palace in New York City. Paul Truex, Thryv’s Chairman of the Board & Chief Executive Officer, will present on November 29th from 3:50 to 4:10 PM in Harlem Track, Kennedy 2, 4th floor.

Mr. Truex will also be available for one-on-one meetings on Wednesday, November 29th. To book one-on-one meetings, please contact admin@thryvtrx.com.

About Thryv Therapeutics Inc.

Thryv Therapeutics Inc. (previously LQT Therapeutics Inc.) is a privately owned company based in Montreal, Quebec, Canada. Thryv Therapeutics is pioneering a precision medicine approach to treat Congenital Long QT Syndromes (LQTS), atrial fibrillation, heart failure and resistant cancers with potent and selective inhibitors of Serum Glucocorticoid inducible Kinase (SGK1). For more information, please visit www.thryvtrx.com.

Media Inquiries

daphne@thryvtrx.com | 514 973 0915

Thryv Therapeutics Presents Benefits of Therapeutic SGK1 Inhibition with THRV-1268 in a Murine Model of Atrial Fibrillation at American Heart Association Scientific Sessions

• Results from obesity-related atrial fibrillation model demonstrate reduced propensity for atrial fibrillation;

• Positive improvements in various pro-inflammatory and pro-fibrotic pathways point to possible role in heart failure;

• On-going in vivo studies with THRV-1268 heart failure models are expected in 2024.

Montreal, Quebec – November 8, 2023 – Thryv Therapeutics Inc., a clinical stage biotechnology company developing therapies for rare diseases including Congenital Long QT Syndrome (LQTS), atrial fibrillation, heart failure and resistant cancers, is pleased to announce an oral presentation of the effects of SGK-1 inhibition with its potent and selective inhibitor THRV-1268 on atrial fibrillation in an obese-mouse model. This abstract will be presented during the Shocking Results: Basic Science Insights into Arrhythmias session at the American Heart Association Annual Scientific Sessions in Philadelphia, PA.

“With an ever-increasing obese population, the incidence of obesity-related atrial fibrillation and heart failure is rising significantly. This pre-clinical study with THRV-1268 demonstrated statistically significant reductions in the frequency of induced arrhythmias and atrial fibrillation-related events in mice fed with a high fat diet.  These data combined with the positive improvement in inflammatory and fibrotic signals proposes this SGK1 inhibitor as a novel therapeutic for the treatment of atrial fibrillation and potentially heart failure.  We look forward to exploring this hypothesis next year in individuals who, despite standard of care, remain at high risk of developing repeated episodes of atrial fibrillation and potential heart failure,” said Pirouz Shamszad, MD, Senior Vice President, Clinical Development at Thryv.

 Atrial fibrillation (Afib) is the most common form of treated arrythmia and has been strongly associated with obesity. Atrial fibrillation may present as a rapid, slow, or abnormal heart rate and may lead to blood clots localized in the heart which can dislodge and increase the risk of stroke, heart failure and other heart-related complications. Obesity is a significant risk factor for the development of atrial fibrillation and a significant driver for the increasing prevalence of atrial fibrillation. Fibrosis, inflammation, and ion channel alteration have been implicated in the pathogenesis of obesity-related atrial fibrillation and heart failure. Atrial fibrillation is a global problem with worldwide prevalence of over 37 million cases, which is expected to further increase 60% by 2050 to an estimated 6 million people affected in the United States.

“Atrial fibrillation remains a challenging disease to treat, particularly in the setting of obesity. As a result, new therapeutic options are needed. These pre-clinical results demonstrate THRV-1268 effectively prevents the induction of obesity-related atrial fibrillation and atrial arrhythmia burden. This is consistent with previous in vivo data where a genetically modified SGK “knock-out” mouse demonstrated similar benefits.  Combined, these data warrant further pre-clinical and eventual clinical investigation,” said Aneesh Bapat, MD, Cardiac Electrophysiologist at Massachusetts General Hospital and Instructor in Medicine, Harvard Medical School, who served as the study’s investigator.

Thryv is also collaborating with Massachusetts General Hospital to conduct additional pre-clinical studies exploring the potential for THRV-1268 as a treatment for heart failure. In this ongoing study at MGH, heart failure is induced in mice through a 15-week regimen that includes a high-fat diet (HFD) intended to activate metabolic stress and L-NAME to induce hypertensive stress.  Subsequently, THRV-1268 is administered for an additional 6 weeks to assess its impact on development of heart failure. It is believed SGK1 inhibition with THRV-1268 will reduce detrimental cardiovascular effects of concurrent metabolic and hypertensive stress through a reduction in fibrosis and inflammation. Data from this study is anticipated to be released in the second quarter of 2024.

About Thryv Therapeutics Inc.

Thryv Therapeutics Inc. (previously LQT Therapeutics Inc.) is a privately owned company based in Montreal, Quebec, Canada. Thryv Therapeutics is pioneering a precision medicine approach to treat Congenital Long QT Syndromes (LQTS), atrial fibrillation, heart failure and resistant cancers with potent and selective inhibitors of Serum Glucocorticoid inducible Kinase (SGK1). For more information, please visit www.thryvtrx.com.

Access the Abstract

https://www.ahajournals.org/doi/10.1161/circ.148.suppl_1.15963

Media Inquiries

daphne@thryvtrx.com | 514 973 0915

Thryv Therapeutics Announces Positive Results from the WAVE 1 Proof of Concept Study. LQT-1213 Rapidly and Meaningfully Reduces QT Interval in Individuals with Prolonged QT Induced by Dofetilide.

Montreal, Quebec – August 25th, 2023 – Thryv Therapeutics Inc. today announced positive results of the WAVE 1 Proof of Concept clinical study evaluating LQT-1213 for the reduction of QTcF in individuals with dofetilide-induced long QT. LQT-1213 is a potent and selective inhibitor of Serum Glucocorticoid inducible Kinase 1 (SGK-1), which is implicated in QTc prolongation.

Long QT Syndrome, or LQTS, is a disorder of the heart’s electrical system causing the lower chambers of the heart to contract and release too slowly. LQTS can be either congenital or acquired.  Congenital LQTS is a set of rare orphan diseases in which people are genetically predisposed to chronic prolongation of their QTc interval (commonly more than 480 milliseconds), leading to increased risk of torsades de pointes, a lethal cardiac arrhythmia that causes sudden cardiac death. Acquired Long QT may develop from the administration of therapies which block electrical pathways in the heart, leading to a similar mechanistic prolongation of QT and risk of sudden cardiac death.

In the WAVE 1 study, mean reductions in QT from baseline (measured as QTcF) were statistically significant beginning at the two-hour time-point on day four of LQT-1213 dosing.  In a predefined subset of individuals who experienced larger dofetilide-induced prolongation of QTcF, individuals treated with LQT-1213 achieved more robust, clinically meaningful reductions of QT consistent with scientific evidence of SGK-1 activation in LQTS.  LQT-1213 was well tolerated with no serious adverse events or treatment related study discontinuations.  No QTcF over-shortening was observed in the study.  There were no observed changes in ECG morphology, heart rate, or blood pressure.  The company plans to present full data from the study at an upcoming scientific meeting.

“Over the past few years, our research has continued to validate the pathogenic role of SGK-1 in rare arrhythmias.  We now have the first in human evidence of the benefits of targeting this activated kinase to reduce prolonged QTc,” commented Philip Sager, MD, Chief Medical Officer of Thryv Therapeutics.  “With this initial safety and efficacy data in hand, clinical testing can commence  in people with Congenital Long QT Syndrome Types 2 and 3, where chronic and substantial QTc prolongation can lead to lethal ventricular arrhythmias.”

In preclinical studies of dofetilide-induced long QT or in experiments utilizing stem cells from individuals with congenital Long QT Syndrome Type 2 and Type 3, LQT-1213 reproducibly and markedly reduced the QTc and APD and, in some cases, fully corrected pathogenic prolongation without any instances of over-shortening.   

“Serum and glucocorticoid regulated kinase (SGK) activity is upregulated in patient-specific induced pluripotent stem cell–derived cardiomyocytes stemming from Long QT Syndrome,” commented Saumya Das, MD, PhD, and Principal Scientific and Medical Advisor of Thryv Therapeutics. “Activation of SGK-1 in the heart markedly increases the late sodium current preferentially leading to prolongation of the action potential duration and an increased propensity to develop arrhythmias.  This latest data builds further on our understanding of the potential for SGK-1 inhibition to provide a new option for individuals with Long QT Syndrome.”

Part two of the WAVE 1 study is currently enrolling a small cohort of patients with congenital Long QT Syndrome Types 2 and 3.  The company anticipates finalizing the results of part one of this study in the coming weeks and discussing the path to registration with the US FDA in early 2024.  Pivotal studies in patients with congenital Long QT Syndromes are anticipated to begin in 2024.

“My daughter’s journey with Long QT Syndrome Type 3 ended abruptly and tragically in October of 2022.  Isla had a very aggressive form of Long QT and despite multiple interventions, shocks from her defibrillator, and unapproved medicines, she was a happy girl who touched the lives of so many.  I’m beyond happy to know that help is on the way, and I know she would be too,” commented David Hutton of Bury, United Kingdom.  David is a founder and trustee of Team 1C, a charity dedicated to raising funds to help parents and families with healthcare costs.  David’s daughter, Isla, passed away at the age of six and a half.  She was diagnosed with Long QT Syndrome Type 3 at birth.

About WAVE 1

Part one of the WAVE 1 crossover study included twenty-three (23) trial completers who received high dose dofetilide, which prolongs QTc and acutely imitates congenital Long QT Syndrome. During the two eight-day clinical study periods individuals received doses of dofetilide and either placebo or three increasing doses of LQT-1213 in a crossover design. Rigorous QTc analyses were performed on days four, six, and eight.  Changes in study participants’ QTc on day four, six and eight were compared to their own placebo time periods throughout the course of the study.

Part two of the WAVE 1 clinical study is currently enrolling a small cohort of individuals with genetically proven Congenital Long QT Syndrome Type 2 and Type 3.  This study will provide information about the safety of LQT-1213 before initiation of clinical studies in congenital LQTS patients.   More about the WAVE 1 (part 1 and 2) can be found at https://www.clinicaltrials.gov/study/NCT05906732.

About Long QT Syndrome

Congenital Long QT Syndrome (LQTS) is a rare genetic condition that causes a prolongation between the beginning of the ECG QRS complex and the end of the T wave, representing cardiac repolarization. The lengthening of the interval can lead to unexpected and life-threatening arrhythmias called torsades de pointes. Studies have demonstrated a direct correlation between the length of the QTc interval and the risk of sudden cardiac death in LQTS patients.  Shortening this interval would result in a reduction of sudden death, syncope, and cardiac arrhythmias in patients with Congenital Long QT Syndrome. More information about Long QT Syndrome can also be found at www.sads.org.

About Thryv Therapeutics

 Thryv Therapeutics Inc. is a privately owned, clinical stage company based in Montreal, Quebec, Canada.  Thryv Therapeutics is pioneering a precision medicine approach to treat genetic and drug-induced Long QT Syndromes, atrial fibrillation, and resistant cancers with potent and selective inhibitors of Serum Glucocorticoid inducible Kinase. For more information, please visit www.thryvtrx.com.

Media Inquiries

daphne@thryvtrx.com | +1 (514) 973 0915

Thryv Therapeutics announces FDA clearance for Phase 1 Study of THRV-1257 in Anaplastic Thyroid Cancer and acceptance of Late-Breaking Poster Presentation at American Thyroid Association Meeting.

• Phase 1 TRIFEKTA clinical study expected to start in Q4 2023.

• Abstract accepted for late breaking poster presentation at 2023 American Thyroid Association annual meeting on September 30th.

Montreal, Quebec – August 15, 2023 – Thryv Therapeutics Inc., a clinical stage biotechnology company developing therapies for rare diseases including Congenital Long QT Syndrome (LQTS), atrial fibrillation, and resistant cancers, announced today FDA clearance of its Investigational New Drug application (IND) for THRV-1257.  THRV-1257 is being investigated for the treatment of advanced Anaplastic Thyroid Cancer (ATC), including those patients with the common BRAF mutation V600E.  The first in human study will determine the optimal dosing of THRV-1257 in patients with solid tumors, followed by treatment in combination with approved cancer therapies.   

At the same time, the company announces acceptance of a late breaking poster that will be presented at the upcoming American Thyroid Association (ATA) annual meeting in Washington DC, on September 30th, 2023, from 10:00 a.m. to 1:00 p.m. The presentation will highlight in vitro and in vivo preclinical results of SGK1 inhibition in models of ATC.

"Preclinical evaluation of our SGK1 inhibitors uncovered novel biology and synergy with existing cancer treatments to extend their activity and reverse resistance.  These studies have revealed a significant opportunity to intervene in several oncology treatment paradigms with an SGK1 inhibitor” said Eric Campeau, Vice President, Translational Research.

According to the ATA, approximately 64,000 people in the United States are diagnosed with thyroid cancer each year. ATC makes up approximately 2% of these cases.  Although ATC is rare compared to other thyroid cancers, it is one of the fastest growing and most aggressive of all cancers. Rapid evaluation and diagnosis are critical for ATC patients, as the disease manifests as a rapidly growing neck mass that impairs speech, swallowing and breathing. Activation of Serine and Glucocorticoid Kinase 1 (SGK1) was determined to be a critical component of ATC cell proliferation, including in tumor cell lines with mutated BRAF. Inhibition of SGK1 was unique in its capacity to suppress ATC cell proliferation compared to other inhibitors tested. Thryv Therapeutics is collaborating with expert scientists and oncologists in ATC to evaluate its SGK1 inhibitors as a potential treatment option to improve the outcome of people with this devastating disease.

“We are excited to advance our portfolio of potent SGK1 inhibitors into the treatment of aggressive, treatment resistant cancers.  SGK1 has been implicated in a number of treatment-resistance oncology pathways and our work has demonstrated the potential to delay resistance and restore activity of approved therapies and ultimately improve progression free and overall survival outcomes,” said Debra Odink, President, and Chief Development Officer.

About Thryv Therapeutics Inc.

Thryv Therapeutics Inc. (previously LQT Therapeutics Inc.) is a privately owned company based in Montreal, Quebec, Canada.  Thryv Therapeutics is pioneering a precision medicine approach to treat genetic and drug-induced Long QT Syndromes, atrial fibrillation, and resistant cancers with potent and selective inhibitors of Serum Glucocorticoid inducible Kinase. For more information, please visit www.thryvtrx.com.

Media Inquiries

daphne@thryvtrx.com | +1 (514) 973 0915